PMC:7600245 / 49983-50215
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T216 | 185-193 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T495 | 11-12 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T373 | 0-232 | Sentence | denotes | Currently, a prospective, randomized, multi-center, double-blinded, and placebo-controlled study is ongoing to evaluate the safety and efficacy of vidofludimus as an adjunct therapy in COVID-19 patients (NCT04379271; n = 230) [157]. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1566 | 194-202 | Species | denotes | patients | Tax:9606 |
| 1569 | 147-159 | Chemical | denotes | vidofludimus | MESH:C553728 |
| 1573 | 185-193 | Disease | denotes | COVID-19 | MESH:C000657245 |